Research programme: CAR T cell therapies - Minovia Therapeutics
Latest Information Update: 25 Sep 2023
At a glance
- Originator Minovia Therapeutics
- Class CAR-T cell therapies; Gene therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Mitochondrial disorders
Most Recent Events
- 19 Jul 2023 Preclinical trials in Mitochondrial disorders in Israel (Parenteral), before July 2023 (Minovia Therapeutics pipeline, July 2023)